Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Comparative Effectiveness of Early Integrated Telehealth versus In-Person Palliative Care for Patients with Advanced Lung Cancer Short Name: REACH PC
Microbiome in immunotherapy na�ve NSCLC patients receiving PD-1/L1 blockade MIP_NSCLC
Study Type: Basic Science
Phase: IV
NCTID: NCT04636775
Principal Investigator:
Jun Zhang
A Phase II Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer NSCLC
Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Evaluation of the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy ? LIVIGNO-4
Study Type: Treatment
Phase: II/III
NCTID: NCT06236438
Principal Investigator:
Jun Zhang
BAY 1895344 Plus Topoisomerase-1 Top1 Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma SCLC, Poorly Differentiated Neuroendocrine Carcinoma PD-NEC and Pancreatic Adenocarcinoma PDA
A Phase I Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
A Phase II Trial of Durvalumab MEDI4736 and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer DARES
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients MicroDurva
Study Type: Basic Science
Phase: IV
NCTID: NCT04680377
Principal Investigator:
Jun Zhang